SCHEMBL26987208

SCHEMBL26987208

O=C1CCN(C(=O)c2ccc(Br)cc2)CC1

nearest known ligand 0.70

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.70
POLB P06746 2/20 0.57
CA12 O43570 1/20 0.57
CA1 P00915 1/20 0.57
CA2 P00918 1/20 0.57
CA7 P43166 1/20 0.57
CA9 Q16790 1/20 0.57
CA14 Q9ULX7 1/20 0.57
L3MBTL3 Q96JM7 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
LMNA P02545 1/20 0.53
ALDH1A1 P00352 1/20 0.52
ABL1 P00519 2/20 0.51
BCR P11274 2/20 0.51
GPR183 P32249 1/20 0.51
MGLL Q99685 1/20 0.51
HSD11B1 P28845 1/20 0.51
KMT2A Q03164 2/20 0.49
EPHX2 P34913 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethylene SCHEMBL8378361 0.96 HPGD (0.66) HPGDPOLBCA12CA1CA2
SCHEMBL24120195 0.90 HPGD (0.61) HPGDPOLBL3MBTL3L3MBTL1LMNA
SCHEMBL28396337 0.89 HPGD (0.61) HPGDPOLBCA12CA1CA2
SCHEMBL27811868 0.83 HPGD (0.53) HPGDCA1CA2CA7CA9
SCHEMBL2987838 0.83 MTHFD2 (0.54) HPGDCA12CA1CA9LMNA
SCHEMBL644199 0.82 HPGD (0.92) HPGDPOLBCA12CA1CA2
SCHEMBL971083 0.82 HPGD (1.00) HPGDPOLBCA12CA1CA2
SCHEMBL8314360 0.81 CA12 (0.58) HPGDCA12CA1CA2CA7
SCHEMBL1799068 0.81 ALDH1A1 (0.64) HPGDPOLBCA12CA1CA2
SCHEMBL7446390 0.81 PKM (0.65) HPGDLMNAALDH1A1MGLLHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4551570-A1 NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF Dong-A ST Co., Ltd. (KR) 2025-05-14 EP disclosed
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof DONG-A ST CO., LTD. (KR) 2025-03-04 US disclosed
CN-119403798-A Novel compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof 东亚ST 株式会社 2025-02-07 CN disclosed
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US disclosed
WO-2024009215-A1 NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof EIF2AK4, GCN1, GCGR HPGD 841/4885POLB 2998/4885CA12 4741/4885
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF EIF2AK4, GCN1, GCGR HPGD 841/4885POLB 2998/4885CA12 4741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.